Automated analysis of a novel anti-epileptic compound, CGP 33 101, and its metabolite, CGP 47 292, in body fluids by high-performance liquid chromatography and liquid-solid extraction

Rouan, Marie-Claude; Souppart, C.; Alif, L.; Moes, Diana; Lecaillon, J.B.; Godbillon, J.

doi:10.1016/0378-4347(95)00026-f

Cited by 24 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are numerous HPLC (Elyas et al, 1990; Rouan et al, 1995; Levert et al, 2002) and GC (Von Unruh & Paar, 1985) methods for the measurement of MHD in serum. More recently, enantioselective HPLC techniques have become available, but their use is primarily for research purposes (Flesch et al, 1992: Volosov et al, 2000; Mazzucchelli et al, 2007).…”

Section: Relevance Of Tdm For Individual Aedsmentioning

confidence: 99%

Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

et al. 2008

View full text Add to dashboard Cite

SUMMARYAlthough no randomized studies have demonstrated a positive impact of therapeutic drug monitoring (TDM) on clinical outcome in epilepsy, evidence from nonrandomized studies and everyday clinical experience does indicate that measuring serum concentrations of old and new generation antiepileptic drugs (AEDs) can have a valuable role in guiding patient management provided that concentrations are measured with a clear indication and are interpreted critically, taking into account the whole clinical context. Situations in which AED measurements are most likely to be of benefit include (1) when a person has attained the desired clinical outcome, to establish an individual therapeutic concentration which can be used at subsequent times to assess potential causes for a change in drug response; (2) as an aid in the diagnosis of clinical toxicity; (3) to assess compliance, particularly in patients with uncontrolled seizures or breakthrough seizures; (4) to guide dosage adjustment in situations associated with increased pharmacokinetic variability (e.g., children, the elderly, patients with associated diseases, drug formulation changes); (5) when a potentially important pharmacokinetic change is anticipated (e.g., in pregnancy, or when an interacting drug is added or removed); (6) to guide dose adjustments for AEDs with dose-dependent pharmacokinetics, particularly phenytoin.

show abstract

Section: Relevance Of Tdm For Individual Aedsmentioning

confidence: 99%

Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

et al. 2008

View full text Add to dashboard Cite

show abstract

“…RFN has received Orphan Drug status in both the European Union and the United States for adjunctive therapy in patients with partial seizures and drop attacks associated with the Lennox-Gastaut syndrome [1]. Two HPLC-UV methods coupled with automated procedures utilizing laboratory robotics have been reported for the determination of RFN in body fluids during early pharmaceutical development [2,3]: after plasma dilution with water RFN was automatically extracted on reversed-phase extraction columns and injected into the HPLC system. Neither of these methods has been validated in plasma of patients with epilepsy.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous HPLC–UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy

Contin

Mohamed

Candela

et al. 2010

Journal of Chromatography B

View full text Add to dashboard Cite

“…The plasma concentrations of rufinamide were determined by high-performance liquid chromatography [2]. Method validation was performed by analysis of a total of 125 plasma samples spiked with rufinamide.…”

Section: Analytical Methods and Pharmacokinetic Evaluationsmentioning

confidence: 99%

“…In both trial arms, about 7 mL venous blood was collected into heparinized Venoject ® tubes immediately before administration of the drug (t= 0) and at 1,2,3,4,6,8,12,16,24,36,48,72, and 96 h afterwards. Immediately after collection the blood samples were centrifuged (2200× g, 5 min at + 4°C), and the plasma was transferred into plain plastic tubes and stored at −20°C until required for analysis.…”

Section: Subjects and Study Designmentioning

confidence: 99%

The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers

Cardot¹,

Lecaillon²,

Czendlik

et al. 1998

Biopharm. Drug Dispos.

Self Cite

View full text Add to dashboard Cite

The effect of food on the pharmacokinetics of the antiepileptic rufinamide was investigated in healthy volunteers. Twelve subjects were treated with single per‐oral doses of 600 mg of rufinamide after overnight fasting or a fat and protein rich breakfast. Mean (±S.D.) areas under the plasma concentration–time curves (AUCs) of the unchanged compound were 57.2 (16) μg mL−1 h when given to the fasted volunteers and 81.7 (22.2) μg mL−1 h (p = 0.0001) when given after the breakfast. The average AUC was increased by 44% when rufinamide was given with food and the maximum concentration (Cmax) by about 100%. The time at which Cmax was reached (tmax) was shorter (8 h in fasted conditions and 6 h in fed after breakfast); the terminal half‐life was not influenced by concomitant intake of food. © 1998 John Wiley & Sons, Ltd.

show abstract

Automated analysis of a novel anti-epileptic compound, CGP 33 101, and its metabolite, CGP 47 292, in body fluids by high-performance liquid chromatography and liquid-solid extraction

Cited by 24 publications

References 3 publications

Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

Simultaneous HPLC–UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy

The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers

Contact Info

Product

Resources

About